The conflicting data in some clinical studies may be explained by various factors: [1] most cohort studies lacked individual validation of fractures as primary outcomes, [2] the studies had short follow-up duration and [3] did not consider important risk factors for osteoporosis such as BMD (even though BMD is not a good method for diagnosing osteoporosis in T2DM), and [4] some studies included medications that affect fracture risk, such as corticosteroids or antidepressants
Regenerative research: Tissue-repair and muscle growth compounds such as BPC-157 and TB-500
While biological plausibility exists, clinicians should recognize that laboratory findings do not automatically translate into proven clinical benefit
Proper cycling and protocol design are key to maintaining receptor sensitivity
John Gabe Horneff, an orthopedic surgeon at Pennsylvania Hospital, had noticed a peculiar trend: Some patients taking GLP-1s would come in with significant tendon injuries from relatively minor physical exertion
Physiologia plantarum, 1994, 13 1: 696-717
